Patisiran-Sodium shortage — AU supply status & alternatives

Patisiran-Sodium

—

In shortage · Australia

ONPATTRO patisiran

In declared shortage · 🇦🇺 Australia

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

✓ Can I substitute?

Yes — approved substitute available

TGA-approved overseas product

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Therapeutic category
Active ingredient (INN)	Patisiran-Sodium
Brand names	ONPATTRO patisiran

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

✓

Section 19A approval in force

Patients are advised to consult their health professional to discuss alternative treatment options. An overseas-registered product has been approved for supply under Section 19A. The approval holder, Medison Pharma Australia Pty Ltd, can be contacted for details on supply on 1800 566 020.

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.